Clinical Trials
4 trialsNCT02614560 2019-01-09
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
Seagen Inc.
Phase 1/2 Terminated
NCT02785900 2018-12-12
CASCADE
Seagen Inc.
Phase 3 Terminated
NCT02326584 2018-05-09
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
Seagen Inc.
Phase 1 Completed
NCT01902329 2018-01-05
A Safety Study of SGN-CD33A in AML Patients
Seagen Inc.
Phase 1 Completed